Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients

doi:10.3969/j.issn.1006-7795.2019.06.018

Journal of Capital Medical University ›› 2019, Vol. 40 ›› Issue (6): 911-915.doi: 10.3969/j.issn.1006-7795.2019.06.018

Previous Articles Next Articles

Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients

Bai Xiangdong¹, Hao Yating¹, Zhang Xinxue², He Qiang²

1. The Third Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan 030013, China;
2. Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2019-06-27 Online:2019-11-21 Published:2019-12-18
Supported by:
This study was supported by National Natural Science Foundation of China(81471590).

Abstract

Abstract: Objective To explore the effect of lineal polypeptide injection combined with chemotherapy on the clinical efficacy in patients with triple-negative breast cancer. Methods Eighty patients with triple-negative breast cancer at Shanxi Provincial Cancer Hospital from January 2014 to December 2017 were enrolled in the study and randomly divided into control group with 40 cases and experimental group with 40 cases. In comparison with the control group treated with conventional postoperative chemotherapy, the experimental group was given the additional lienal polypeptide injection on the basis of the control group. The immunological function and clinical efficacy were compared. Results After treatment, the Karnofsky functional status score of the experimental group was significantly higher than that of the control group(F=5.793,P=0.018), and the proportion of CD4⁺ (t=5.337, P<0.001), CD8⁺(t=9.874,P<0.001), natural killer cell (NK) (t=-7.460,P<0.001) and Treg cells(t=7.113, P<0.001) were all increased to different degrees. The progress-free survival period (PFS) of the experimental group was longer than that of the control group, and the difference between the two groups was statistically significant (P<0.05).However, there was no statistically significant difference in the rate of upper limb lymphedema (P>0.05). Conclusion Lineal polypeptide injection can effectively improve the immune function and enhance the general life of triple-negative breast cancer patients.

Key words: triple-negative breast cancer, lienal polypeptide injection (LPI), progress-free survival period, immune function, upper limb lymphedema

CLC Number:

R737.9

Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients[J]. Journal of Capital Medical University, 2019, 40(6): 911-915.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.06.018

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I6/911

References

[1] Gelmon K, Dent R, Mackey J R, et al. Targeting triple-negative breast cancer:optimising therapeutic outcomes[J]. Ann Oncol, 2012, 23(9):2223-2234.
[2] Bai X, Han G, Liu Y, et al. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3[J]. Biomed Pharmacother,2018,103:1482-1489.
[3] Christenson J L, Butterfield K T, Spoepstra N S, et al. MMTV-PyMT and derived met-1 mouse mammary tumor cells as models for studying the role of the androgen receptor in triple-negative breast cancer progression[J].Horm Cancer, 2017,8(2):69-77.
[4] 王姝姝,胡保全,齐晓伟,等.新辅助化疗和辅助化疗治疗三阴性乳腺癌患者预后差异的回顾性研究[J].中华乳腺病杂志,2018,12(4):229-233.
[5] Wu Y P, Deng J, Ouyang S H, et al. Immune regulation effect of lienal polypeptides extract in Lewis lung carcinoma-bearing mice treated with cyclophosphamide[J]. Exp Biol Med (Maywood), 2018,243(1):66-77.
[6] 李文军,于代华,宗雷,等. 脾多肽注射液对脓毒症患者血清炎症因子及免疫功能的影响[J].陕西医学杂志,2019,48(4):463-466.
[7] 代平,王于理,王金辉,等.脾多肽对晚期卵巢癌化疗引起骨髓抑制影响[J].中华肿瘤防治杂志,2018,25(6):437-441.
[8] 王丹丹,陈伟贤,夏文晋,等.脾多肽联合化疗治疗乳腺癌的临床疗效观察[J].中国现代医学杂志,2017,27(3):93-96.
[9] 代平,王于理,王金辉,等.脾多肽对晚期卵巢癌化疗引起骨髓抑制影响[J].中华肿瘤防治杂志,2018,25(6):437-441.
[10] 战祥毅,隋鑫,王文萍. 乳腺癌术后上肢淋巴水肿治疗进展[J].临床军医杂志,2016,44(12):1305-1309.
[11] 王惠雪,李惠萍,杨娅娟,等.空气波压力治疗仪在预防及治疗乳腺癌术后淋巴水肿效果Meta分析[J].中华肿瘤防治杂志,2017,24(11):773-778.
[12] 宋聪睿,白玲,唐英,等.乳腺癌前哨淋巴结转移相关因素分析[J].中华肿瘤防治杂志,2016,23(18):1234-1238,1243.
[13] 鲍艳红,李薇,李青.三联疗法对乳腺癌术后上肢肿胀患者免疫功能和炎性因子的影响[J].河北医药,2018,7(40):2123-2126.
[14] 王翠娟,尚明,邵华.芳香烃受体在肿瘤发生及免疫治疗中的作用[J].中华肿瘤防治杂志,2018,25(15):1126-1130.
[15] 骆成玉.乳腺癌治疗从标准到精准微创[J].首都医科大学学报,2016,37(3):331-335.

Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

Comments

[1]	Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Effects of combined lienal polypeptide injection and postoperative chemotherapy on estrogen receptor-positive and estrogen receptor-negative patients [J]. Journal of Capital Medical University, 2019, 40(3): 443-448.
[2]	Yang Wei;Yang Huasheng;He Xiujuan;Li Xiuhui;Qian Ying. Clinical Observation of 65 Cases with Hepatocellular Carcinoma Treated by Huqisan and Transeatheter Arterial Chemoembolization [J]. Journal of Capital Medical University, 2009, 30(1): 37-40.
[3]	Wu Baoyu;Yuan Shenyuan;Wei Min;Li Boguang. A Preliminary Study on RBC Immune Function in Rats with Experimental Membranous Glomerulonephritis [J]. Journal of Capital Medical University, 1999, 20(3): 178-180.
[4]	Zhang Chuankai;Yuan Shengrong;Liu Jinxue. Effect of Water Extract of Cordyceps sinensis and Paecilomyces sinensis on Immune Function in Mice [J]. Journal of Capital Medical University, 1999, 20(1): 17-20.
[5]	Li Yulan;Li Yuying;An Yunqing;Yan Peisun;Liu Dongmei. The Effect of Monosodium Glutamate on the Growth and Immue Function in Rat [J]. Journal of Capital Medical University, 1997, 18(3): 218-221.